Latest News

• FDA-Designated Breakthrough Therapy Available in PCCTC Clinical T...

  Press Releases by admin August 5, 2016

  

  The US Food and Drug Administration (FDA) recently granted Novartis’ CDK4/6 inhibitor LEE011 (ribociclib), in combination with letrozole, Breakthrough Therapy...

  Learn More

• PCCTC Facilitates Groundbreaking Prostate Cancer Gene Sequencing ...

  Press Releases by admin July 7, 2016

  

  Men with metastatic disease found more likely to harbor mutations in genes mediating DNA-repair processes, according to results published Wednesday in the New E...

  Learn More

• CDMRP Releases FY16 Clinical Consortium Research Site Award

  Press Releases by admin June 28, 2016

  

  The US Department of Defense (DoD) Prostate Cancer Research Program (PCRP), a division of its Congressionally Directed Medical Research Programs (CDMRP) relea...

  Learn More

• PCCTC Collaborates with Florence Healthcare to Enhance Regulatory...

  Press Releases by admin June 10, 2016

  

  ATLANTA, GA and NEW YORK, June 10, 2016 – Florence Healthcare, developer of the innovative trial site-focused electronic trial site and master file (eTMF) pla...

  Learn More

• PCCTC Investigators Establish Guidelines for CRPC Clinical Trials...

  Press Releases by admin May 31, 2016

  

  The latest recommendations from Prostate Cancer Working Group 3 (PCWG3) have already been implemented into many clinical trials supported by the PCCTC...

  Learn More

• VT-464, Drug in Development with PCCTC, Fast Tracked by FDA

  Press Releases by WRAL TechWire January 8, 2016

  

  Innocrin's CYP17 lyase inhibitor seviteronel (VT-464), currently in PCCTC-led early phase clinical development, is granted fast track designation for patients w...

  Learn More